Rennova Health

RNVA · OTC

$0.00+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

Key indicators

RNVA profitability and balance sheet ratios

EPS -$0.0002 in Dec 2023, against $0.00 a year earlier.

EPS by quarter
PeriodEPS
Mar 2022-$0.4712
Jun 2022-$0.0003
Sep 2022-$0.0001
Dec 2022$0.00
Mar 2023$0.00
Jun 2023$0.00
Sep 2023-$0.00
Dec 2023-$0.0002

Where the money went

Q3 FY17, from revenue to net income

Rennova Health brought in $0.8M of revenue in Q3 FY17, +1858.5% on a year earlier. It made a net loss of $13.1M.

Revenue
$0.8M
Costs, expenses and taxes
$13.9M
Net income
−$13.1M
Net margin
-1617.8%

Income statement

Revenue and profit by reporting period

Revenue
Net income
RNVA income statement, quarterly
Line itemQ1 FY17Q2 FY17Q3 FY17
Revenue$0.7M$0.1M$0.8M
Gross profit$0.4M−$0.1M$0.5M
Operating income−$3.6M−$3.9M−$4.5M
Net income−$49.7M−$14.2M−$13.1M
Diluted EPS-$0.67-$28.02-$10.90

Balance sheet

What the company owns and owes at period end

Total assets
Total liabilities
RNVA balance sheet, quarterly
Line itemJun 2023Sep 2023Dec 2023
Total assets$21.6M$19.8M$20.3M
Total liabilities$48.6M$47.4M$57.1M
Shareholder equity−$27.0M−$27.6M−$36.8M
Cash and short-term investments$0.7M$0.1M$0.0M
Total debt$12.0M$11.8M$11.4M

Cash flow

Cash in and out from operations, investing and financing

Operating
Investing
Financing
RNVA cash flow, quarterly
Line itemQ1 FY17Q2 FY17Q3 FY17
Operating cash flow−$6.0M−$2.7M−$3.2M
Investing cash flow−$1.1M−$0.3M−$0.2M
Financing cash flow$8.3M$1.6M$3.4M
Capital expenditure−$1.1M−$0.3M−$0.2M
Free cash flow−$7.1M−$3.0M−$3.3M

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.